An Iranian familial amyotrophic lateral sclerosis pedigree with p.Val48Phe causing mutation in SOD1: a genetic and clinical report

Document Type: Original Article

Authors

1 School of Biology, College of Science, University of Tehran, Tehran, Iran

2 Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran

Abstract

Objective(s): Amyotrophic lateral sclerosis (ALS), a fatal progressive neurodegenerative disorder, is the most common motor neuron disease in European populations. Approximately 10% of ALS cases are familial (FALS) and the other patients are considered as sporadic ALS (SALS). Among many ALS causing genes that have been identified, mutations in SOD1 and C9orf72 are the most common genetic causes of the disease. In Iranian patients, it has been shown that SOD1, as compared to C9orf72, plays a much more prominent role.  To date, more than 170 mutations have been reported in SOD1. Genotype/phenotype correlation with respect to either different causative genes or different mutations of a specific gene has not been well established. 
Materials and Methods: Five exons of SOD1 and flanking intronic sequences of an Iranian FALS proband were screened for mutations by direct sequencing. Also, the clinical features of the proband were described.
Results: Heterozygous p.Val48Phe causing mutation was identified in SOD1. Age at onset was 29 years and site of the first presentation was the lower extremity in the proband.
Conclusion: The p.Val48Phe causing mutation appears to cause early onset of ALS.

Keywords


1. Nelson LM. Epidemiology of ALS. Clin Neurosci 1996; 3:327–331.

2.Charcot JM, Joffroy A. Deux cas d’atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere. Arch Physiol Neurol Pathol 1869; 2:744.

3. Rowland L, Shneider N. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344:1688–16700.

4.Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri a R, Zalutsky R. How common are the “common” neurologic disorders? Neurology 2007; 68:326–337.

5. Rison R a, Beydoun SR. Amyotrophic lateral sclerosis-motor neuron disease, monoclonal gammopathy, hyperparathyroidism, and B12 deficiency: case report and review of the literature. J Med Case Pep 2010; 4:298.

6. Sabatelli M, Conte a, Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin Gene 2013; 83:408–416.

7. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis  2009; 4:3.

8. Shirakawa K, Suzuki H, Ito M, Kono S, Uchiyama T, Ohashi T, et al. Novel compound heterozygous ALS2 mutations cause juvenile amyotrophic lateral sclerosis in Japan. Neurology 2009; 73:2124–2126.

9. Andersen PM, Forsgren L, Binzer M, Nilsson P, Ala-Hurula V, Keränen ML, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119:1153–1172.

10. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007; 6:994–1003.

11.Alavi A, Nafissi S, Rohani M, Zamani B, Sedighi B, Shamshiri H, et al. Genetic analysis and SOD1 mutation screening in Iranian amyotrophic lateral sclerosis patients. Neurobiol Aging 2013; 34:1516.e1–8.

12. Sapp PC, Rosen DR, Hosler B a, Esteban J, McKenna-Yasek D, O’Regan JP, et al. Identification of three novel mutations in the gene for Cu/Zn superoxide dismutase in patients with familial amyotrophic lateral sclerosis. Neuromusc Dis 1995; 5:353–357.

13. Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006; 6:37–46.

14. Wroe R, Wai-Ling Butler A, Andersen P, Powell JF, Al-Chalabi A. ALSoD: the amyotrophic lateral sclerosis online database. Amyotroph Lateral Scler 2008; 9:249–250.

15. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011; 7:603–615.

16. Ince PG, Highley JR, Kirby J, Wharton SB, Takahashi H, Strong MJ, et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011; 122:657–671.

17. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72:245–256.

18. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72:257–268.

19. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 

hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 4422:1–8.

20.Ogaki K, Li Y, Atsuta N, Tomiyama H, Funayama M, Watanabe H, et al. Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiol Aging 2012; 33:2527.e11–6.

21.          Tsai C-P, Soong B-W, Tu P-H, Lin K-P, Fuh J-L, Tsai P-C, et al. A hexanucleotide repeat expansion in C9ORF72 causes familial and sporadic ALS in Taiwan. Neurobiol Aging  2012; 33:2232.e11–2232.e18.

22. Alavi A, Nafissi S, Rohani M, Shahidi G, Zamani B, Shamshiri H, et al. Repeat expansion in C9ORF72 is not a major cause of amyotrophic lateral sclerosis among Iranian patients. Neurobiol Aging 2014; 35:267.e1e267.e7

23. Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 2011; 71:281–288.

24. Rosen DR, Siddique T, Patterson D, Figlewicz D, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59–62.

25. Gellera C. Genetics of ALS in Italian families. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2:S43–46.

26. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler Other Motor Neuron Disord 2000; 1:293–299.

27. Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. Arch Neurol 2012; 69:1410–1416.

28. Ticozzi N, Tiloca C, Morelli C, Colombrita C, Poletti B, Doretti A, et al. Genetics of familial Amyotrophic lateral sclerosis. Arch Ital Biol 2011; 149:65–82.

29.Sapp PC, Rosen DR, Hosler B a, Esteban J, McKenna-Yasek D, O’Regan JP, et al. Identification of three novel mutations in the gene for Cu/Zn superoxide dismutase in patients with familial amyotrophic lateral sclerosis. Neuromusc Disord 1995; 5:353–357.

30. Sabatelli M, Conte a, Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin Genet 2013; 83:408–416.